A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes



Status:Recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:July 25, 2017
End Date:June 30, 2019
Contact:Jeff C Huffman
Email:jhuffman@partners.org
Phone:617-724-2910

Use our guide to learn which trials are right for you!

A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes: a 16-week Randomized Controlled Trial

The focus of this study is to examine the feasibility, acceptability, and impact of a
customized, combined positive psychology and motivational interviewing (PP-MI) health
behavior intervention in a group of patients with type 2 diabetes (T2D).

The investigators will compare a combined positive psychology and motivational interviewing
(PP-MI) intervention that is adapted for patients with T2D to a diabetes education
intervention (control) in a randomized controlled trial. The investigators will enroll 70
participants, who will be randomized to either a 16-week PP-MI health behavior intervention
or an 16-week diabetes education intervention.

In this project, the investigators plan to do the following:

1. Examine the feasibility and acceptability of a 16-week, telephone-delivered health
behavior intervention utilizing PP exercises and MI with systematic goal-setting.

2. Determine whether the PP-MI intervention leads to greater increases in physical activity
than the education intervention in T2D patients.

3. Explore the impact of the PP-MI intervention on other psychological, behavioral, and
medical outcomes, compared to the education intervention.

Participants will undergo an initial screening visit during which they will meet with study
staff in person. At this visit, study eligibility will be confirmed, and eligible and willing
participants will be enrolled. Following enrollment, participants will complete self-report
measures, and vital signs and A1c will be measured. They then will take home and wear an
accelerometer for one week, to measure baseline physical activity.

Baseline information about enrolled participants will be obtained from the participants, care
providers, and the electronic medical record as required for characterization of the
population. This information will include data regarding medical history (type 2 diabetes
mellitus), current medical variables (conditions affecting physical activity), medications,
and sociodemographic data (age, gender, race/ethnicity, living alone).

Participants will undergo a second in-person visit once adequate baseline physical activity
data has been obtained. In this visit, accelerometer data will be reviewed to ensure that
adequate baseline activity was captured. If so, participants will be randomized to either the
PP-MI or diabetes education condition, then begin the study intervention. During this second
in-person visit, participants will receive either a PP-MI or diabetes education treatment
manual, depending on randomization.

For the PP-MI intervention:

For each session, a PP exercise will be described in the manual, with instructions and space
to write about the exercise and its effects. Next, an MI section will outline specific
MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity
goal-setting. At subsequent sessions, participants will review the prior week's PP exercise
and learn about a new exercise, then will review the prior week's physical activity goal and
set a new one.

For the diabetes education intervention:

Each week, participants will learn about a different health behavior topic related to
diabetes health. This includes information about diabetes self-monitoring, medication
adherence, having a heart-healthy diet, and being physically active.

Participants will complete the remaining sessions by phone approximately weekly over the next
16 weeks. Phone sessions will last approximately 30 minutes, with PP-MI and physical activity
assignments completed between phone sessions. PP and MI will be delivered step-wise within
sessions (rather than intertwined) based on our experience, participant feedback, and pilot
work. If a week is missed, the session will not be skipped, but rather the intervention will
be completed sequentially (with participants who miss weeks then missing the final sessions),
with the exception of the final visit, which skips to Planning for the Future in all cases.

Participants will undergo an in-person follow-up assessment at 16 weeks. At this session,
participants will repeat self-report assessments that were administered at baseline. Vital
signs and a blood sample will again be collected at this in-person visit. Prior to this
assessment, participants will wear an accelerometer for 7 days to measure physical activity.
Participants will also undergo a phone follow-up assessment at 24 weeks. During this session
over the phone, participants will repeat self-report assessments that were administered at
baseline. Finally, prior to this follow-up, participants will wear another accelerometer for
7 days to measure physical activity.

Inclusion Criteria:

1. T2D. Eligible patients will meet American Diabetes Association (ADA) criteria for T2D
(e.g., HbA1c [A1C] ≥6.5%, fasting glucose ≥126 mg/d), with diagnosis confirmed by
their diabetes clinician and/or medical record review.

2. Low physical activity. Low physical activity will be defined as ≤150 minutes/week of
MVPA (corresponding to ADA recommendations for moderate or greater intensity aerobic
physical activity). Physical activity will be measured using a brief questionnaire
adapted from the International Physical Activity Questionnaire (IPAQ).

Exclusion Criteria:

1. Cognitive impairment precluding consent or meaningful participation.

2. Lack of phone availability.

3. Inability to read/write in English.

4. Additional medical conditions (e.g., severe arthritis) that preclude physical
activity.

5. Enrollment in mind-body programs, lifestyle intervention programs (e.g., cardiac
rehabilitation), or other clinical trials.
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Jeff C Huffman, MD
?
mi
from
Boston, MA
Click here to add this to my saved trials